Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT00384592 Completed - Clinical trials for Gastro-Oesophageal Reflux Disease

PPI Sequencing Study

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

NCT ID: NCT00382850 Completed - Clinical trials for Gastroesophageal Reflux

Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children

Start date: November 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether short- and long-term outcomes are different between open and laparoscopic Nissen fundoplication performed in children younger than 2 years of age.

NCT ID: NCT00378898 Completed - Clinical trials for Gastroesophageal Reflux Disease

Feasibility of Placing Bravo PH Capsule in Proximal Esophagus

bravo
Start date: September 2006
Phase: N/A
Study type: Interventional

Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus. There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal monitor.

NCT ID: NCT00373997 Completed - Clinical trials for Gastroesophageal Reflux

Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux

biopsy I
Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether patients with suspected Laryngopharyngeal reflux have inflammation and ultrastructural injury on their laryngeal biopsies.

NCT ID: NCT00373334 Completed - Clinical trials for Gastroesophageal Reflux Disease

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.

NCT ID: NCT00367614 Completed - Clinical trials for Gastroesophageal Reflux

Study Evaluating Pantoprazole in Adolescents With GERD

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is characterize the PK profile of single and multiple doses of pantoprazole in adolescents aged 12 to 16 years with Gastroesophageal Reflux Disease (GERD).

NCT ID: NCT00365300 Completed - Clinical trials for Gastroesophageal Reflux

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

Start date: September 2006
Phase: Phase 3
Study type: Interventional

To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).

NCT ID: NCT00362609 Completed - Clinical trials for Gastroesophageal Reflux

Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD

Start date: July 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether or not consistent drug levels can be achieved in infants with presumed Gastroesophageal Reflux Disease.

NCT ID: NCT00361972 Completed - Asthma Clinical Trials

Elucidation of Acid-Induced Pulmonary Inflammation

Start date: August 2006
Phase: Phase 2/Phase 3
Study type: Interventional

We propose to study how heartburn may lead to different types of inflammation in one's airways. Additionally, we hope to determine whether aggressive treatment of heartburn results in improvement in both symptoms of heartburn and asthma but also in documented improvement in airway inflammation as determined by biopsy. The results of this study will be important in directing future research into the relationship between heartburn and asthma and may provide a clue whether certain subtypes of asthma may be caused primarily by GER.

NCT ID: NCT00354757 Completed - GERD Clinical Trials

CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing

Start date: June 2005
Phase: Phase 4
Study type: Interventional

Background/Aim: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P (CYP) 2C19 polymorphism in a population with a high prevalence of people who poorly metabolize PPIs. Patients and Methods: In this randomized, open-label trial, patients with symptoms suggestive of GERD were randomized to receive a two-week test with 20-mg or 40-mg rabeprazole after diagnostic endoscopy. Symptom response was assessed with a four-grade daily record; in addition, DNA from peripheral blood leukocytes was genotyped for CYP2C19 polymorphism with polymerase chain reaction-restrict fragment length polymorphism (PCR-RFLP) technique.